{"id":"https://openalex.org/W2148570339","doi":"https://doi.org/10.1517/13543784.2010.535516","title":"Farnesyltransferase inhibitors: where are we now?","display_name":"Farnesyltransferase inhibitors: where are we now?","publication_year":2010,"publication_date":"2010-11-18","ids":{"openalex":"https://openalex.org/W2148570339","doi":"https://doi.org/10.1517/13543784.2010.535516","mag":"2148570339","pmid":"https://pubmed.ncbi.nlm.nih.gov/21083522"},"language":"en","primary_location":{"id":"doi:10.1517/13543784.2010.535516","doi":"https://doi.org/10.1517/13543784.2010.535516","is_oa":false,"landing_page_url":"https://doi.org/10.1517/13543784.2010.535516","pdf_url":null,"source":{"id":"https://openalex.org/S131064935","display_name":"Expert Opinion on Investigational Drugs","issn_l":"1354-3784","issn":["1354-3784","1744-7658"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Opinion on Investigational Drugs","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5044840107","display_name":"Apostolia Maria Tsimberidou","orcid":"https://orcid.org/0000-0003-2713-233X","observed_orcids":["https://orcid.org/0000-0003-2713-233X"]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Apostolia Maria Tsimberidou","raw_affiliation_strings":["University of Texas M.D. Anderson Cancer Center, Investigational Cancer Therapeutics, 1515 Holcombe Blvd., Unit 455, Houston 77030, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Texas M.D. Anderson Cancer Center, Investigational Cancer Therapeutics, 1515 Holcombe Blvd., Unit 455, Houston 77030, USA","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108500682","display_name":"Chandtip Chandhasin","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1343551460","display_name":"The University of Texas MD Anderson Cancer Center","ror":"https://ror.org/04twxam07","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1343551460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Chandtip Chandhasin","raw_affiliation_strings":["University of Texas M.D. Anderson Cancer Center, Investigational Cancer Therapeutics, 1515 Holcombe Blvd., Unit 455, Houston 77030, USA rkurzroc@mdanderson.org"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Texas M.D. Anderson Cancer Center, Investigational Cancer Therapeutics, 1515 Holcombe Blvd., Unit 455, Houston 77030, USA rkurzroc@mdanderson.org","institution_ids":["https://openalex.org/I1343551460"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5053481267","display_name":"Razelle Kurzrock","orcid":"https://orcid.org/0000-0003-4110-1214","observed_orcids":["https://orcid.org/0000-0003-4110-1214"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Razelle Kurzrock","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":3.4048,"has_fulltext":false,"cited_by_count":39,"citation_normalized_percentile":{"value":0.93158124,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"19","issue":"12","first_page":"1569","last_page":"1580"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9648000001907349,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9648000001907349,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12104","display_name":"Protein Tyrosine Phosphatases","score":0.0071000000461936,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11559","display_name":"Retinoids in leukemia and cellular processes","score":0.006399999838322401,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/farnesyltransferase-inhibitors","display_name":"farnesyltransferase inhibitors","score":1.0},{"id":"https://openalex.org/keywords/tipifarnib","display_name":"tipifarnib","score":0.9990000128746033},{"id":"https://openalex.org/keywords/acute-myeloid-leukemia","display_name":"acute myeloid leukemia","score":0.9629999995231628},{"id":"https://openalex.org/keywords/myelodysplastic-syndrome","display_name":"myelodysplastic syndrome","score":0.9399999976158142},{"id":"https://openalex.org/keywords/hematologic-malignancies","display_name":"hematologic malignancies","score":0.7369999885559082},{"id":"https://openalex.org/keywords/solid-tumors","display_name":"solid tumors","score":0.6600000262260437},{"id":"https://openalex.org/keywords/patient-selection","display_name":"patient selection","score":0.6869999766349792},{"id":"https://openalex.org/keywords/hydroxyurea","display_name":"hydroxyurea","score":0.7630000114440918},{"id":"https://openalex.org/keywords/complete-response","display_name":"complete response","score":0.4950000047683716},{"id":"https://openalex.org/keywords/targeted-therapy","display_name":"targeted therapy","score":0.37599998712539673}],"concepts":[{"id":"https://openalex.org/C2778396349","wikidata":"https://www.wikidata.org/wiki/Q410994","display_name":"Farnesyltransferase","level":4,"score":0.8419333100318909},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6731186509132385},{"id":"https://openalex.org/C2777827897","wikidata":"https://www.wikidata.org/wiki/Q5436005","display_name":"Farnesyltransferase inhibitor","level":5,"score":0.5566399097442627},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.5119081735610962},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4804486930370331},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.47124984860420227},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.3593007028102875},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.15034431219100952},{"id":"https://openalex.org/C57790582","wikidata":"https://www.wikidata.org/wiki/Q901141","display_name":"Prenylation","level":3,"score":0.08854341506958008},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0},{"id":"https://openalex.org/C181199279","wikidata":"https://www.wikidata.org/wiki/Q8047","display_name":"Enzyme","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D002986","descriptor_name":"Clinical Trials as Topic","qualifier_ui":"Q000379","qualifier_name":"methods","is_major_topic":false},{"descriptor_ui":"D004791","descriptor_name":"Enzyme Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D004791","descriptor_name":"Enzyme Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D004791","descriptor_name":"Enzyme Inhibitors","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000201","qualifier_name":"enzymology","is_major_topic":false},{"descriptor_ui":"D011905","descriptor_name":"Genes, ras","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D011905","descriptor_name":"Genes, ras","qualifier_ui":"Q000502","qualifier_name":"physiology","is_major_topic":false},{"descriptor_ui":"D015363","descriptor_name":"Quinolones","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D015363","descriptor_name":"Quinolones","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D015363","descriptor_name":"Quinolones","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D051231","descriptor_name":"Farnesyltranstransferase","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D051231","descriptor_name":"Farnesyltranstransferase","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1517/13543784.2010.535516","doi":"https://doi.org/10.1517/13543784.2010.535516","is_oa":false,"landing_page_url":"https://doi.org/10.1517/13543784.2010.535516","pdf_url":null,"source":{"id":"https://openalex.org/S131064935","display_name":"Expert Opinion on Investigational Drugs","issn_l":"1354-3784","issn":["1354-3784","1744-7658"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert Opinion on Investigational Drugs","raw_type":"journal-article"},{"id":"pmid:21083522","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/21083522","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Expert opinion on investigational drugs","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9940000176429749}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":92,"referenced_works":["https://openalex.org/W194463696","https://openalex.org/W1558058709","https://openalex.org/W1564880184","https://openalex.org/W1594384581","https://openalex.org/W1603593764","https://openalex.org/W1805968117","https://openalex.org/W1847774702","https://openalex.org/W1873121398","https://openalex.org/W1967323308","https://openalex.org/W1972540178","https://openalex.org/W1973097976","https://openalex.org/W1974740049","https://openalex.org/W1980827197","https://openalex.org/W1984429541","https://openalex.org/W1990095100","https://openalex.org/W2007327754","https://openalex.org/W2018650005","https://openalex.org/W2018958796","https://openalex.org/W2024196844","https://openalex.org/W2025754007","https://openalex.org/W2025778935","https://openalex.org/W2036082581","https://openalex.org/W2037480365","https://openalex.org/W2051626784","https://openalex.org/W2054459787","https://openalex.org/W2058897102","https://openalex.org/W2060438880","https://openalex.org/W2064050813","https://openalex.org/W2064335255","https://openalex.org/W2073342804","https://openalex.org/W2074661496","https://openalex.org/W2077777928","https://openalex.org/W2078174274","https://openalex.org/W2079207880","https://openalex.org/W2090195452","https://openalex.org/W2093132545","https://openalex.org/W2096710550","https://openalex.org/W2100545037","https://openalex.org/W2102895088","https://openalex.org/W2102901804","https://openalex.org/W2104811481","https://openalex.org/W2104978230","https://openalex.org/W2112185977","https://openalex.org/W2114029145","https://openalex.org/W2114260801","https://openalex.org/W2115068822","https://openalex.org/W2118053238","https://openalex.org/W2118546226","https://openalex.org/W2119575895","https://openalex.org/W2121495250","https://openalex.org/W2122900341","https://openalex.org/W2125673665","https://openalex.org/W2129056290","https://openalex.org/W2131353030","https://openalex.org/W2132915056","https://openalex.org/W2133311724","https://openalex.org/W2134771869","https://openalex.org/W2135753750","https://openalex.org/W2136099575","https://openalex.org/W2137343757","https://openalex.org/W2137566722","https://openalex.org/W2138396354","https://openalex.org/W2139938477","https://openalex.org/W2140135539","https://openalex.org/W2141356595","https://openalex.org/W2141817518","https://openalex.org/W2143568970","https://openalex.org/W2143578354","https://openalex.org/W2145188827","https://openalex.org/W2150242923","https://openalex.org/W2155008672","https://openalex.org/W2156654096","https://openalex.org/W2158801409","https://openalex.org/W2163405261","https://openalex.org/W2164553008","https://openalex.org/W2166927952","https://openalex.org/W2167590728","https://openalex.org/W2167734044","https://openalex.org/W2168313669","https://openalex.org/W2168623442","https://openalex.org/W2172104048","https://openalex.org/W2225138096","https://openalex.org/W2244255040","https://openalex.org/W2248127540","https://openalex.org/W2248329128","https://openalex.org/W2255894651","https://openalex.org/W2324953630","https://openalex.org/W2333809012","https://openalex.org/W2416619555","https://openalex.org/W2461848005","https://openalex.org/W2590188240","https://openalex.org/W2950122139"],"related_works":["https://openalex.org/W2059542017","https://openalex.org/W2063584629","https://openalex.org/W2102287185","https://openalex.org/W2089420365","https://openalex.org/W2133764101","https://openalex.org/W78193929","https://openalex.org/W2091566589","https://openalex.org/W1759110377","https://openalex.org/W2402069987","https://openalex.org/W2010269862"],"abstract_inverted_index":{"IMPORTANCE":[0],"OF":[1],"THE":[2,32],"FIELD:":[3],"Farnesyltransferase":[4],"inhibitors":[5],"(FTIs)":[6],"target":[7],"multiple":[8],"pathways":[9],"implicated":[10],"in":[11,77,115,128,192],"the":[12,129,188,193],"pathogenesis":[13],"of":[14,37,40,63,190,195],"solid":[15,199],"and":[16,26,81,88,98,141,198],"hematologic":[17],"malignancies.":[18],"AREAS":[19],"COVERED":[20],"IN":[21],"THIS":[22],"REVIEW:":[23],"Novel":[24],"preclinical":[25],"clinical":[27,38],"data":[28],"on":[29],"FTIs.":[30],"WHAT":[31],"READER":[33],"WILL":[34],"GAIN:":[35],"Results":[36],"trials":[39,175],"FTIs":[41,182,191],"are":[42],"critically":[43],"summarized:":[44],"Phase":[45,104],"I":[46],"-":[47,86,90,96,100],"II":[48],"studies":[49],"demonstrated":[50],"that":[51,144],"tipifarnib":[52,108,130],"(the":[53],"most":[54],"extensively":[55],"investigated":[56],"FTI)":[57],"had":[58],"antileukemic":[59],"activity.":[60],"The":[61],"rates":[62],"complete":[64],"response":[65,68,140],"(CR),":[66],"partial":[67],"(PR)":[69],"and/or":[70],"CR":[71],"with":[72,79,109,117,153],"incomplete":[73],"platelet":[74],"recovery":[75],"(CRp)":[76],"patients":[78,116,152,177],"MDS":[80],"refractory/poor-risk":[82],"AML":[83,119,154],"were":[84],"5":[85],"25%":[87],"11":[89],"14%,":[91],"respectively":[92],"(hematological":[93],"improvement,":[94],"17":[95],"35%":[97],"8":[99],"9.5%,":[101],"respectively).":[102],"A":[103,132],"III":[105],"study":[106],"comparing":[107],"best":[110],"supportive":[111],"care,":[112],"including":[113],"hydroxyurea":[114],"untreated":[118],"\u2265":[120],"70":[121],"years":[122],"old":[123],"showed":[124],"no":[125],"survival":[126],"benefit":[127,157,180],"arm.":[131],"two-gene":[133,146],"classifier":[134],"(RASGRP1:APTX":[135],"gene":[136],"expression":[137,147],"ratio)":[138],"predicted":[139],"survival,":[142],"indicating":[143],"a":[145,167],"assay":[148],"may":[149],"help":[150],"select":[151],"who":[155,178],"would":[156,179],"from":[158,181],"tipifarnib.":[159],"TAKE":[160],"HOME":[161],"MESSAGE:":[162],"Patient":[163],"selection":[164],"should":[165,183],"become":[166],"priority":[168],"for":[169],"targeted":[170],"agent":[171],"drug":[172],"development.":[173],"Clinical":[174],"selecting":[176],"be":[184],"designed":[185],"to":[186],"define":[187],"role":[189],"treatment":[194],"hematological":[196],"malignancies":[197],"tumors.":[200]},"counts_by_year":[{"year":2023,"cited_by_count":2},{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":2},{"year":2017,"cited_by_count":3},{"year":2016,"cited_by_count":3},{"year":2015,"cited_by_count":3},{"year":2014,"cited_by_count":7},{"year":2013,"cited_by_count":7},{"year":2012,"cited_by_count":8}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}